PE20011229A1 - 4-bencil-1-[2-(4-hidroxi-fenoxi)-etil]-piperidin-3,4-diol como bloqueadores del receptor n-metil-d-aspartato - Google Patents
4-bencil-1-[2-(4-hidroxi-fenoxi)-etil]-piperidin-3,4-diol como bloqueadores del receptor n-metil-d-aspartatoInfo
- Publication number
- PE20011229A1 PE20011229A1 PE2001000359A PE2001000359A PE20011229A1 PE 20011229 A1 PE20011229 A1 PE 20011229A1 PE 2001000359 A PE2001000359 A PE 2001000359A PE 2001000359 A PE2001000359 A PE 2001000359A PE 20011229 A1 PE20011229 A1 PE 20011229A1
- Authority
- PE
- Peru
- Prior art keywords
- piperidin
- phenoxy
- diol
- benzyl
- hydroxy
- Prior art date
Links
- QDLSQZUNQXEAFR-UHFFFAOYSA-N 4-benzyl-1-[2-(4-hydroxyphenoxy)ethyl]piperidine-3,4-diol Chemical compound C1CC(CC=2C=CC=CC=2)(O)C(O)CN1CCOC1=CC=C(O)C=C1 QDLSQZUNQXEAFR-UHFFFAOYSA-N 0.000 title abstract 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title 1
- 230000004770 neurodegeneration Effects 0.000 abstract 4
- 230000001154 acute effect Effects 0.000 abstract 2
- QDLSQZUNQXEAFR-VQTJNVASSA-N (3s,4s)-4-benzyl-1-[2-(4-hydroxyphenoxy)ethyl]piperidine-3,4-diol Chemical compound C([C@@H]([C@](CC1)(O)CC=2C=CC=CC=2)O)N1CCOC1=CC=C(O)C=C1 QDLSQZUNQXEAFR-VQTJNVASSA-N 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
- C07D211/50—Aroyl radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00108769 | 2000-04-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20011229A1 true PE20011229A1 (es) | 2001-12-08 |
Family
ID=8168543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000359A PE20011229A1 (es) | 2000-04-25 | 2001-04-19 | 4-bencil-1-[2-(4-hidroxi-fenoxi)-etil]-piperidin-3,4-diol como bloqueadores del receptor n-metil-d-aspartato |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6432985B2 (OSRAM) |
| EP (1) | EP1278730B1 (OSRAM) |
| JP (1) | JP3831255B2 (OSRAM) |
| KR (1) | KR100527527B1 (OSRAM) |
| CN (1) | CN1178914C (OSRAM) |
| AR (1) | AR028357A1 (OSRAM) |
| AT (1) | ATE313527T1 (OSRAM) |
| AU (1) | AU785153B2 (OSRAM) |
| BR (1) | BR0110233A (OSRAM) |
| CA (1) | CA2407345C (OSRAM) |
| DE (1) | DE60116080T2 (OSRAM) |
| DK (1) | DK1278730T3 (OSRAM) |
| ES (1) | ES2254422T3 (OSRAM) |
| MX (1) | MXPA02010573A (OSRAM) |
| PE (1) | PE20011229A1 (OSRAM) |
| UY (1) | UY26681A1 (OSRAM) |
| WO (1) | WO2001081309A2 (OSRAM) |
| ZA (1) | ZA200208134B (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7640062B2 (en) | 2000-05-08 | 2009-12-29 | Brainsgate Ltd. | Methods and systems for management of alzheimer's disease |
| WO2004043218A2 (en) | 2002-11-14 | 2004-05-27 | Brainsgate Ltd. | Surgical tools and techniques for stimulation |
| US7684859B2 (en) | 2002-04-25 | 2010-03-23 | Brainsgate Ltd. | Stimulation of the OTIC ganglion for treating medical conditions |
| US7005432B2 (en) * | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
| US8010189B2 (en) * | 2004-02-20 | 2011-08-30 | Brainsgate Ltd. | SPG stimulation for treating complications of subarachnoid hemorrhage |
| US8055347B2 (en) | 2005-08-19 | 2011-11-08 | Brainsgate Ltd. | Stimulation for treating brain events and other conditions |
| US9233245B2 (en) | 2004-02-20 | 2016-01-12 | Brainsgate Ltd. | SPG stimulation |
| EP1976495A2 (en) * | 2006-01-06 | 2008-10-08 | Aarhus Universitet | Compounds acting on the serotonin transporter |
| CN101754761B (zh) * | 2007-05-21 | 2014-06-18 | 雷维瓦药品公司 | 基于喹啉酮的非典型抗精神病药的组合物、合成和使用方法 |
| US8008253B2 (en) * | 2007-07-03 | 2011-08-30 | Andrew Tasker | Treatment for anxiety |
| US7860569B2 (en) | 2007-10-18 | 2010-12-28 | Brainsgate, Ltd. | Long-term SPG stimulation therapy for prevention of vascular dementia |
| KR20100135847A (ko) * | 2008-03-27 | 2010-12-27 | 에보텍 뉴로사이언시즈 게엠베하 | Ｎｍｄａ ｎｒ２ｂ―서브타입 선택적 길항제를 사용한 질병 치료 방법 |
| NZ710443A (en) | 2008-08-12 | 2019-03-29 | Zinfandel Pharmaceuticals Inc | Method of identifying disease risk factors |
| US8846315B2 (en) | 2008-08-12 | 2014-09-30 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
| AU2012205798B2 (en) | 2011-01-10 | 2016-02-25 | Takeda Pharmaceutical Company Limited | Methods and drug products for treating Alzheimer's disease |
| US8703763B2 (en) * | 2011-03-02 | 2014-04-22 | Hoffmann-La Roche Inc. | Bridged piperidine derivatives |
| US9675796B2 (en) | 2013-11-10 | 2017-06-13 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
| US10633336B2 (en) | 2014-12-19 | 2020-04-28 | The Broad Institute, Inc. | Dopamine D2 receptor ligands |
| WO2016100823A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute, Inc. | Dopamine d2 receptor ligands |
| EP3093043B1 (en) | 2015-05-13 | 2018-11-14 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
| JP7132218B2 (ja) * | 2016-11-08 | 2022-09-06 | エフ．ホフマン－ラ ロシュ アーゲー | フェノキシトリアゾール |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9610745B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
| ZA9610738B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | Subtype selective nmda receptor ligands and the use thereof |
| TW498067B (en) | 1996-07-19 | 2002-08-11 | Hoffmann La Roche | 4-hydroxy-piperidine derivatives |
-
2001
- 2001-03-19 US US09/811,888 patent/US6432985B2/en not_active Expired - Fee Related
- 2001-04-17 EP EP01933833A patent/EP1278730B1/en not_active Expired - Lifetime
- 2001-04-17 DE DE60116080T patent/DE60116080T2/de not_active Expired - Lifetime
- 2001-04-17 AT AT01933833T patent/ATE313527T1/de not_active IP Right Cessation
- 2001-04-17 CA CA002407345A patent/CA2407345C/en not_active Expired - Fee Related
- 2001-04-17 ES ES01933833T patent/ES2254422T3/es not_active Expired - Lifetime
- 2001-04-17 AU AU60213/01A patent/AU785153B2/en not_active Ceased
- 2001-04-17 KR KR10-2002-7014261A patent/KR100527527B1/ko not_active Expired - Fee Related
- 2001-04-17 WO PCT/EP2001/004305 patent/WO2001081309A2/en not_active Ceased
- 2001-04-17 DK DK01933833T patent/DK1278730T3/da active
- 2001-04-17 BR BR0110233-8A patent/BR0110233A/pt not_active Application Discontinuation
- 2001-04-17 CN CNB018085911A patent/CN1178914C/zh not_active Expired - Fee Related
- 2001-04-17 JP JP2001578404A patent/JP3831255B2/ja not_active Expired - Fee Related
- 2001-04-17 MX MXPA02010573A patent/MXPA02010573A/es active IP Right Grant
- 2001-04-19 PE PE2001000359A patent/PE20011229A1/es not_active Application Discontinuation
- 2001-04-23 AR ARP010101869A patent/AR028357A1/es active IP Right Grant
- 2001-04-24 UY UY26681A patent/UY26681A1/es not_active Application Discontinuation
-
2002
- 2002-10-09 ZA ZA200208134A patent/ZA200208134B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2407345A1 (en) | 2001-11-01 |
| UY26681A1 (es) | 2001-10-25 |
| EP1278730B1 (en) | 2005-12-21 |
| BR0110233A (pt) | 2003-01-21 |
| AU6021301A (en) | 2001-11-07 |
| DK1278730T3 (da) | 2006-05-01 |
| KR100527527B1 (ko) | 2005-11-09 |
| WO2001081309A3 (en) | 2002-01-17 |
| ZA200208134B (en) | 2004-01-22 |
| CA2407345C (en) | 2009-04-07 |
| JP2004509837A (ja) | 2004-04-02 |
| ATE313527T1 (de) | 2006-01-15 |
| WO2001081309A2 (en) | 2001-11-01 |
| US20010047014A1 (en) | 2001-11-29 |
| US6432985B2 (en) | 2002-08-13 |
| CN1178914C (zh) | 2004-12-08 |
| MXPA02010573A (es) | 2003-03-10 |
| EP1278730A2 (en) | 2003-01-29 |
| AR028357A1 (es) | 2003-05-07 |
| JP3831255B2 (ja) | 2006-10-11 |
| AU785153B2 (en) | 2006-10-05 |
| KR20040007216A (ko) | 2004-01-24 |
| CN1443166A (zh) | 2003-09-17 |
| DE60116080D1 (de) | 2006-01-26 |
| ES2254422T3 (es) | 2006-06-16 |
| DE60116080T2 (de) | 2006-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20011229A1 (es) | 4-bencil-1-[2-(4-hidroxi-fenoxi)-etil]-piperidin-3,4-diol como bloqueadores del receptor n-metil-d-aspartato | |
| CL2008003787A1 (es) | Compuestos derivados de heteroarilo, antagonistas del receptor de orexina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos del sueno, trastornos psiquiatricos, neurologicos, ansiedad, depresion, esquizofrenia, alzheimer, parkinson, entre otras. | |
| UY30426A1 (es) | Derivados sustituidos del 3-(4-metoxi-fenil)-3h-isoindol-1-ilamina trifluoroacetado, sus sales o solvatos farmaceuticamente aceptables, formulaciones farmacéuticas y aplicaciones. | |
| MA33428B1 (fr) | Agonistes du gpr119 | |
| NZ595571A (en) | Pyrazole compounds and uses thereof | |
| BR0311177A (pt) | (imidazol-1-il-metil)-piridazina como bloqueador de receptores de nmda | |
| UY29927A1 (es) | Derivados sustituidos de la 5-fenil-2-tioxo-imidazolin-4-ona y de la 5-fenil-2-amino-imidazolidin-4-ona y sus sales, composiciones y aplicaciones | |
| MX2010009561A (es) | Compuestos amida, composiciones y usos de los mismos. | |
| UA83691C2 (ru) | Применение замещенных 2-аминотетралинов для упреждающего лечения болезни паркинсона | |
| AR062841A1 (es) | Tratamiento del dolor, diabetes, y trastornos del metabolismo de los lipidos | |
| PT2139334E (pt) | Compostos heterocíclicos fusionados de 2-cianofenilo, e composições e utilizações dos mesmos | |
| MA31849B1 (fr) | Nouveaux dérivés de pyrimidine | |
| BRPI0409611A (pt) | derivados de piperazina e uso dos mesmos para o tratamento de doenças neurológicas e psiquiátricas | |
| GEP20146099B (en) | Fused imidazole carboxamides as trpv3 modulators | |
| MA29222B1 (fr) | Composition cosmetique a application cutanee appropriee pour detendre de rides d'expression | |
| ATE544756T1 (de) | Substituierte carbinolverbindungen | |
| GEP20135913B (en) | 1-benzyl-3-hydroxymethylindazole derivatives and use thereat treatment of diseases based on mcp-1 and cx3cr1 expression | |
| BR0317005A (pt) | Processo para a preparação de compostos ativos opticamente puros | |
| JP2004509837A5 (OSRAM) | ||
| MX2009011852A (es) | Composiciones que comprenden compuestos macrolidos de alcoxieter de c-13 y compuestos de fenilpirazol. | |
| EP1750667A4 (en) | COMBINATION OF FOSFOMYCIN / AMINOGLYCOSIDE IN AEROSOL FOR THE TREATMENT OF BACTERIAL ANTOPWAY INFECTIONS | |
| MA31742B1 (fr) | Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique | |
| MA28562B1 (fr) | 1,3,4-oxadiazol-2-ones comme modulateurs de ppar delta et leur utilisation | |
| MY128818A (en) | Ethanesulfonyl-piperidine derivatives | |
| AR054779A1 (es) | N-(2,2-dimetilpropil)-6-{3-fluoro-5-[(3-isoxazolilamino)carbonil]-2-metilfenil}-3-piridinacarboxamida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |